trial

CRT-Guanfacine for SPD

NCTId NCT02524899
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 45 (actual)
Sponsored by Icahn School of Medicine at Mount Sinai
Primary completion 2017-01-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-01
Primary completion
2017-01-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cognitive Remediation TherapyGuanfacine

Sponsors

Icahn School of Medicine at Mount SinaiLead Sponsor
Brain & Behavior Research FoundationCollaborator

Investigators

1
Margaret McNamara McClure, Ph.D.Principal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
CRT-Guanfacine for SPD — primary completion2017-01-10

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE2
Primary Completion Date
2017-01-10
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Remediation Therapy
drug
Guanfacine
drug
lead_sponsor
Icahn School of Medicine at Mount Sinai
company
collaborator
Brain & Behavior Research Foundation
company
indication
Personality Disorders
indication
Schizotypal Personality Disorder
indication
Cognitive Dysfunction
indication
investigator
Margaret McNamara McClure, Ph.D.
person